Abu Dhabi’s (DoH) Policy on Assisted Reproductive Services

By HEOR Staff Writer

February 17, 2023

Understanding THIQA’s Policy on Assisted Reproductive Services

THIQA’s policy outlines the eligibility criteria, benefits, and reimbursement packages for Assisted Reproductive Techniques (ART) in Abu Dhabi. It is not a clinical management guideline, but rather a framework to ensure eligible patients in need of ART treatments receive coverage based on evidence-based medical criteria.

Determining Medical Necessity in Assisted Reproductive Treatments

THIQA covers Assisted Reproductive treatments deemed medically necessary. This could be due to a couple trying for pregnancy for at least a year, or one or both individuals diagnosed with infertility problems. Infertility can also be diagnosed prior to one year if there are features or findings indicative of subfertility, such as oligo or amenorrhea, history of pelvic infection, or abnormality in semen parameters.

Eligibility and Covered Services

The preferred age range for women seeking fertility is between 18-47 years. Exceptions apply for fertility preservation in female patients diagnosed with cancer. The Body Mass Index (BMI) eligibility range is from 19-40. Covered services include treatment, oocyte and embryo cryopreservation, transfer of embryos, medications, in vitro fertilisation (IVF), and genetic investigations.

The Future of Assisted Reproductive Services

The policy is a testament to the commitment of THIQA and other life sciences consulting firms to provide value-based healthcare. With advancements in artificial intelligence consulting services, we can expect more personalised and effective treatments in the future.

 

Reference url

Recent Posts

Advancing Health Technology Assessment MENA: Insights and Implications for the Region

By HEOR Staff Writer

March 31, 2026

In this article we provide an update on the current state of Health Technology Assessment (HTA) across the Middle East and North Africa (MENA) region. Health Technology Assessment MENA remains at an early stage of development despite its vital role in evaluating the medical, economic, ethical, an...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity

By João L. Carapinha

January 6, 2026

Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...
Publication Delays Impact Careers of Early-Career Researchers

By João L. Carapinha

May 19, 2025

The article “Dear editors, your publication delays are damaging our careers” by Chia-Hsuan Hsu highlights how publication delays hurt careers, especially for early-career researchers. With publication records key for jobs and tenure, slow editorial processes stall academic progress. The author sh...